RVNC News and Press, Revance Therapeutics Inc. From 02/15/19

CareDx (NASDAQ: CDNA ) initiated with Buy rating and $35 (46% upside) price target at Jefferies. More news on: CareDx, Inovalon, Revance Therapeutics, Inc., Healthcare stocks news, , Read more ...

Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release f...

MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and ...

NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of International Paper Company (NYSE:IP), Gray Television, Inc. (NYSE:GTN), ...

Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Neutral rating at UBS. More news on: Alnylam Pharmaceuticals, Inc., Atara Biotherapeutics, Elanco, Healthcare stocks news, Stocks on the move, , Read more ...

- Completes Type B Pre-BLA meeting with U.S. FDA for glabellar lines indication and remains on track to submit application in first half of 2019 - - Initiates Phase 2 trials for RT002 in both plantar fasciitis and adult upper limb spasticity - Revance Therapeutics, Inc. (NASDAQ:RVNC)...

Deals and Financings WuXi AppTec (SHA: 603259), China's largest CRO/CMO, completed a $1 billion IPO on the Hong Kong markets, pricing the offering in the middle of the expected range. In May, WuXi became a public company by completing a $328 million IPO in Shanghai. Since the offering, the...

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Credit Suisse Healthcare Conference in Phoenix, AZ. President an...

Revance Therapeutics, Inc. (RVNC) Q3 2018 Earnings Conference Call November 1, 2018, 16:30 ET Executives Jeanie Herbert - Senior Director of IR & Corporate Communications Daniel Browne - Co-Founder, CEO, President & Director Cyril Allouche - Head of Finance, Interim Princ...

Revance Therapeutics (NASDAQ: RVNC ): Q3 GAAP EPS of -$0.91 beats by $0.12 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...